ANT3310 is an inhibitor of broad-spectrum covalent Serine β-Lactamase with IC50s ranging from 1 nM to 175 nM for AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2. ANT3310 can be used in studies about bacterial infection.

ANT3310 shows a low in vitro cytotoxicity (IC50 > 100 μM), cardiotoxicity (inhibition of the hERG potassium ion channel) and genotoxicity in HepG2 cell. ANT3310 (0.006 to 3 000 nM) inhibits a series of Serine β-Lactamase including AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2, with IC<>50 values ranging from 1 nM to 175 nM[1].

In male Swiss albino mice, ANT3310 (1 mg/kg; i.v.) shows a T1/2 value of 0.64 h, AUC value of 412 ng•h/mL, and Cl value of 40 mL/min/kg. In the murine thigh infection model, ANT3310 (25, 50 and 100 mg/kg; i.v.) reduces bacterial burdens in a dose-dependent manner to levels below that of the initial starting inoculum at the highest dose, when treated with the combination of MEM[1].